IP Library Granted Patent US 8,487,157
Granted Patent B2
US 8,487,157 · App. 12/812,731 · Granted Jul 16, 2013

Transgenic rodents having NGF beta gene mutants and its preparation methods, the preparation methods of the corresponding mutant proteins and the resulting mutant proteins

Inventors: Zhiwen Zhou (Beijing, CN); Hongshan Zhang (Beijing, CN); Hongbo Chen (Beijing, CN)
Assignee: Staidson (Beijing) Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,487,157
App. No.
12/812,731
Granted
Jul 16, 2013
Kind
B2
Abstract

Transgenic rodents having NGF beta gene mutants in their genomes express NGF beta mutant proteins. The preparation methods of the transgenic rodents, the methods of utilizing the transgenic animals to prepare NGF beta mutant proteins and the resulting NGF beta mutant proteins are provided. The transgenic rodents are useful in preparing human NGF and in the study of the functions of NGF beta mutants and their receptors in the whole animal level, and also useful for screening and purifying NGF beta mutants which have high activity and high security.

Claims (13)

1. A transgenic mouse, wherein a polynucleotide sequence encoding a NGF-β protein in the genome of said mouse is replaced with a polynucleotide sequence encoding a human NGF-β protein by homologous recombination, wherein said polynucleotide sequence encoding a human NGF-β protein is the nucleotide sequence of SEQ ID NO: 23, and wherein said mouse expresses said human NGF-β protein.

2. The transgenic mouse of claim 1 , wherein said polynucleotide sequence encoding a human NGF-β protein is present in at least one chromosome of said genome of said mouse.

3. The transgenic mouse of claim 1 , wherein all NGF-β genes in said genome of said mouse comprise said polynucleotide sequence encoding a human NGF-β protein.

4. A method for obtaining the transgenic mouse of claim 1 , said method comprising substituting the coding sequence of the endogenous NGF-β gene of a mouse by homologous recombination with a polynucleotide sequence encoding a human NGF-β protein wherein said method comprises the steps of:

1) constructing a targeting vector, wherein said vector comprises a polynucleotide sequence encoding a human NGF-β protein, wherein said polynucleotide sequence encoding a human NGF-β protein is the nucleotide sequence of SEQ ID NO:23;

2) using the targeting vector obtained in step 1) to transfect mouse embryonic stem cells;

3) preparing a donor mouse blastocyst;

4) microinjecting the transfected embryonic stem cells obtained in step 2) into the donor blastocyst obtained in step 3);

5) transferring the donor blastocyst obtained in step 4) to the uterus of an acceptor mouse; and

6) obtaining the transgenic mouse.

5. A method of preparing a human NGF-β protein, comprising the steps of:

1) feeding the transgenic mouse of claim 1 , wherein said mouse expresses said human NGF-β protein, and

2) extracting said human NGF-β protein from the submandibular glands of said mouse.

Assignments (2)
CHANGE OF NAME Recorded Sep 8, 2016
From: STAIDSON (BEIJING) PHARMACEUTICAL CO., LTD.
To: STAIDSON (BEIJING) BIOPHARMACEUTICAL CO., LTD.
Reel/Frame 039950/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2010
From: ZHOU, ZHIWEN; ZHANG, HONGSHAN; CHEN, HONGBO
To: STAIDSON (BEIJING) PHARMACEUTICAL CO., LTD.
Reel/Frame 025442/0044 →
Priority Claims (1)
CN 2007 1 0086017 · Mar 7, 2007 · national
Continuity (1)
Related Publication 20110082285A1 · Apr 7, 2011